A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma.
Clinical studies suggest that treatment with vaccines comprised of idiotype protein may be associated with improved clinical outcome in follicular lymphoma patients. The time-consuming process required to generate patient-specific vaccines is a major limitation, however. Here we report results of a pilot clinical trial with a novel autologous, tumor-derived proteoliposome vaccine formulation that could be rapidly produced within a single day. Vaccination was safe, induced autologous tumor-specific type 1 cytokine responses in 5 out of 10 follicular lymphoma patients, and was associated with induction of a sustained complete response in one patient. Other patients had large tumor burdens and progressed after a median duration of 8 months. These results suggest that further testing of this vaccine formulation, particularly in the setting of minimal disease, is warranted. Furthermore, the proteoliposome formulation may provide a model for vaccine development for other human cancers, for which tumor-associated antigens need not be defined.
Neelapu
Sattva S
SS
Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. sneelapu@mdanderson.org
Gause
Barry L
BL
Harvey
Linda
L
Lee
Seung-Tae
ST
Frye
Andrea Robin
AR
Horton
Jessie
J
Robb
Richard J
RJ
Popescu
Mircea C
MC
Kwak
Larry W
LW
D000328:Adult; D019496:Cancer Vaccines / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use; D016207:Cytokines / Q000187:drug effects; D005260:Female; D006801:Humans; D007109:Immunity; D008224:Lymphoma, Follicular / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011510:Proteolipids / Q000627:therapeutic use*; D047368:Tumor Burden / Q000187:drug effects
D019496:Cancer Vaccines; D016207:Cytokines; D011510:Proteolipids; C020485:proteoliposomes